Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avutometinib + Abemaciclib + Fulvestrant in Metastatic HR+/HER2- Breast Cancer
NCT05608252Phase 2Recruiting
- Sponsor
- Adrienne G. Waks
- Start
- Feb 2023
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of avutometinib in Breast cancer (hormone receptor-positive/human epidermal growth factor receptor 2-negative), sponsored by Adrienne G. Waks. Started Feb 2023; status: recruiting.
02
Drugs
avutometinib
03
Conditions
Breast cancer (hormone receptor-positive/human epidermal growth factor receptor 2-negative)
Beyond the preview
Go deeper on NCT05608252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05608252.